{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:13:35Z","timestamp":1793042015690,"version":"4.5.0"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031514","name":"Health Commission of Chengdu Municipality","doi-asserted-by":"publisher","award":["WXLH202405010"],"award-info":[{"award-number":["WXLH202405010"]}],"id":[{"id":"10.13039\/100031514","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Melanoma is the most aggressive form of skin cancer. Although immune checkpoint inhibitors (ICIs) have led to major therapeutic breakthroughs, monotherapy remains limited by suboptimal response rates and pronounced resistance. In recent years, combination strategies integrating ICIs with anti-angiogenic agents have demonstrated substantial synergistic antitumor potential. This review systematically summarizes the mechanisms underlying this synergy, including cross-regulation between immune checkpoints and angiogenic factors (such as VEGF and ANG-2), the remodeling of the tumor immune microenvironment by anti-angiogenic agents, and feedback regulation of angiogenesis by ICIs. Preclinical studies indicate that such combinations can induce vascular normalization and enhance T-cell infiltration, thereby reversing immunosuppression. Subsequently, multiple clinical studies have confirmed that, compared with ICI monotherapy, combination therapy provides superior efficacy and acceptable safety in patients with advanced, mucosal, acral, and even brain-metastatic melanoma. Although the combined approach may increase adverse events such as cardiovascular complications and dermatologic toxicity, these risks can be controlled through multidisciplinary management. Overall, ICI-based combination therapy with anti-angiogenic agents represents a promising therapeutic paradigm for melanoma. Future research should focus on biomarker discovery and optimization of individualized precision strategies to maximize patient survival benefits.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1760044","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T06:59:00Z","timestamp":1770879540000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Tumor immune-vascular crosstalk: synergy and translation of immune checkpoint inhibitors and anti-angiogenic agents in melanoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Yijie","family":"Xie","sequence":"first","affiliation":[{"name":"Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]},{"name":"Key Laboratory of Acupuncture for Senile Disease (Chengdu University of Traditional Chinese Medicine (TCM)), Ministry of Education\/Acupuncture and Chronobiology Key Laboratory of Sichuan Province","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Ho","sequence":"additional","affiliation":[{"name":"Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]},{"name":"Key Laboratory of Acupuncture for Senile Disease (Chengdu University of Traditional Chinese Medicine (TCM)), Ministry of Education\/Acupuncture and Chronobiology Key Laboratory of Sichuan Province","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]},{"name":"Key Laboratory of Acupuncture for Senile Disease (Chengdu University of Traditional Chinese Medicine (TCM)), Ministry of Education\/Acupuncture and Chronobiology Key Laboratory of Sichuan Province","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]},{"name":"Key Laboratory of Acupuncture for Senile Disease (Chengdu University of Traditional Chinese Medicine (TCM)), Ministry of Education\/Acupuncture and Chronobiology Key Laboratory of Sichuan Province","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjie","family":"Zhou","sequence":"additional","affiliation":[{"name":"Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]},{"name":"Key Laboratory of Acupuncture for Senile Disease (Chengdu University of Traditional Chinese Medicine (TCM)), Ministry of Education\/Acupuncture and Chronobiology Key Laboratory of Sichuan Province","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guodong","family":"Ha","sequence":"additional","affiliation":[{"name":"Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]},{"name":"Key Laboratory of Acupuncture for Senile Disease (Chengdu University of Traditional Chinese Medicine (TCM)), Ministry of Education\/Acupuncture and Chronobiology Key Laboratory of Sichuan Province","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lincheng","family":"Duan","sequence":"additional","affiliation":[{"name":"Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]},{"name":"Key Laboratory of Acupuncture for Senile Disease (Chengdu University of Traditional Chinese Medicine (TCM)), Ministry of Education\/Acupuncture and Chronobiology Key Laboratory of Sichuan Province","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]},{"name":"Key Laboratory of Acupuncture for Senile Disease (Chengdu University of Traditional Chinese Medicine (TCM)), Ministry of Education\/Acupuncture and Chronobiology Key Laboratory of Sichuan Province","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingjun","family":"Cai","sequence":"additional","affiliation":[{"name":"Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]},{"name":"Key Laboratory of Acupuncture for Senile Disease (Chengdu University of Traditional Chinese Medicine (TCM)), Ministry of Education\/Acupuncture and Chronobiology Key Laboratory of Sichuan Province","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3491","article-title":"Melanoma epidemiology and sun exposure","volume":"100","author":"Raimondi","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-022-10029-3","article-title":"The cure from within? A review of the microbiome and diet in melanoma","volume":"41","author":"Kumar","year":"2022","journal-title":"Cancer Metastasis Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s43556-024-00200-3","article-title":"Gut microbiome influences efficacy of endostatin combined with pd-1 blockade against colorectal cancer","volume":"5","author":"Xu","year":"2024","journal-title":"Mol BioMed"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001179","article-title":"Skin immunization for effective treatment of multifocal melanoma refractory to pd1 blockade and braf inhibitors","volume":"9","author":"Hao","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.955063","article-title":"Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures","volume":"13","author":"Hossain","year":"2022","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12967-023-04200-9","article-title":"The role of mitochondria in the resistance of melanoma to pd-1 inhibitors","volume":"21","author":"Du","year":"2023","journal-title":"J Transl Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00496-y","article-title":"Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes","volume":"18","author":"Huinen","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.10.025","article-title":"Melanoma cell intrinsic gaba(a) receptor enhancement potentiates radiation and immune checkpoint inhibitor response by promoting direct and T cell-mediated antitumor activity","volume":"109","author":"Pomeranz Krummel","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006467","article-title":"Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: A short report","volume":"11","author":"de Joode","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02437-1","article-title":"Checkpoint inhibitors and anti-angiogenic agents: A winning combination","volume":"129","author":"Brest","year":"2023","journal-title":"Br J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4401","article-title":"Rationale for immune checkpoint inhibitors plus targeted therapy in metastatic melanoma: A review","volume":"6","author":"Dummer","year":"2020","journal-title":"JAMA Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.802846","article-title":"The research progress of antiangiogenic therapy, immune therapy and tumor microenvironment","volume":"13","author":"Hu","year":"2022","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01751-7","article-title":"Rationale of using immune checkpoint inhibitors (Icis) and anti-angiogenic agents in cancer treatment from a molecular perspective","volume":"25","author":"Sherafat","year":"2025","journal-title":"Clin Exp Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01041","article-title":"Role of serum vascular endothelial growth factor (Vegf) as a potential biomarker of response to immune checkpoint inhibitor therapy in advanced melanoma: results of a pilot study","volume":"10","author":"Khattak","year":"2020","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.949553","article-title":"Ang2-targeted combination therapy for cancer treatment","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1487610","article-title":"Leveraging the synergy between anti-angiogenic therapy and immune checkpoint inhibitors to treat digestive system cancers","volume":"15","author":"Xu","year":"2024","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.cytogfr.2024.08.001","article-title":"Targeting pd-1\/pd-L1 in tumor immunotherapy: mechanisms and interactions with host growth regulatory pathways","volume":"79","author":"Shen","year":"2024","journal-title":"Cytokine Growth Factor Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.616837","article-title":"Direct and indirect modulation of T cells by vegf-a counteracted by anti-angiogenic treatment","volume":"12","author":"Bourhis","year":"2021","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.157347","article-title":"Lenvatinib or anti-vegf in combination with anti-pd-1 differentially augments antitumor activity in melanoma","volume":"8","author":"Tran","year":"2023","journal-title":"JCI Insight"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1551322","article-title":"Ifn-\u0393-mediated suppression of angpt2-tie2 in endothelial cells facilitates tumor vascular normalization during immunotherapy","volume":"16","author":"Cai","year":"2025","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1035323","article-title":"Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade","volume":"13","author":"Zheng","year":"2022","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.bbrc.2023.04.018","article-title":"Dc101, an anti-vegfr2 agent, promotes high-endothelial venule formation and immune infiltration versus sar131675 and fruquintinib","volume":"661","author":"Wang","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-22-2838","article-title":"Angiopoietin-2-dependent spatial vascular destabilization promotes T-cell exclusion and limits immunotherapy in melanoma","volume":"83","author":"Park","year":"2023","journal-title":"Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-025-01539-z","article-title":"The inhibition of endothelial dll4-notch1 signaling by 2\u2019-hydroxyflavanone enhances anti-pd-1 therapy in melanoma","volume":"48","author":"You","year":"2025","journal-title":"Arch Pharm Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01956","article-title":"Anti-angiogenic agents in combination with immune checkpoint inhibitors: A promising strategy for cancer treatment","volume":"11","author":"Song","year":"2020","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003318","article-title":"Combining ctla-4 and angiopoietin-2 blockade in patients with advanced melanoma: A phase I trial","volume":"9","author":"Ott","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.584903","article-title":"Neoangiogenesis in melanoma: an issue in biology and systemic treatment","volume":"11","author":"Quaresmini","year":"2020","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-22-1528","article-title":"Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: A multicenter, open-label, single-arm phase ii study","volume":"28","author":"Mao","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e70169","DOI":"10.1002\/ctm2.70169","article-title":"Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3-year survival update and multi-omics analysis","volume":"15","author":"Dai","year":"2025","journal-title":"Clin Transl Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/jco-24-02219","article-title":"Phase ii trial of pembrolizumab in combination with bevacizumab for untreated melanoma brain metastases","volume":"43","author":"Weiss","year":"2025","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/jco.22.00221","article-title":"Phase ii leap-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination","volume":"41","author":"Arance","year":"2023","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.793","article-title":"Phase ii clinical trial of neoadjuvant anti-pd-1 (Toripalimab) combined with axitinib in resectable mucosal melanoma","volume":"35","author":"Lian","year":"2024","journal-title":"Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.1363","article-title":"Camrelizumab plus apatinib and temozolomide as first-line treatment in patients with advanced acral melanoma: the cap 03 phase 2 nonrandomized clinical trial","volume":"9","author":"Mao","year":"2023","journal-title":"JAMA Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-14-0053","article-title":"Bevacizumab plus ipilimumab in patients with metastatic melanoma","volume":"2","author":"Hodi","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122563","article-title":"Vegf\/vegfr axis and its signaling in melanoma: current knowledge toward therapeutic targeting agents and future perspectives","volume":"345","author":"Malekan","year":"2024","journal-title":"Life Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.00210","article-title":"Axitinib in combination with toripalimab, a humanized immunoglobulin G(4) monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase ib trial","volume":"37","author":"Sheng","year":"2019","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous nsclc","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.06.006","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 keynote-426 study","volume":"84","author":"Plimack","year":"2023","journal-title":"Eur Urol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00686-2","article-title":"The multiple roles of ldh in cancer","volume":"19","author":"Claps","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41419-025-08023-y","article-title":"Lactate-mediated histone lactylation promotes melanoma angiogenesis via il-33\/st2 axis","volume":"16","author":"Zhao","year":"2025","journal-title":"Cell Death Dis"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01206-x","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.122.19427","article-title":"Vegf (Vascular endothelial growth factor) inhibition and hypertension: does microvascular rarefaction play a role","volume":"80","author":"le Noble","year":"2023","journal-title":"Hypertension"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.747416","article-title":"Safety profile of immunotherapy combined with antiangiogenic therapy in patients with melanoma: analysis of three clinical studies","volume":"12","author":"Tian","year":"2021","journal-title":"Front Pharmacol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1127128","article-title":"Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: A real-world pharmacovigilance analysis based on the faers database from 2014 to 2022","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104059","article-title":"Comparing cardiovascular adverse events in cancer patients: A meta-analysis of combination therapy with angiogenesis inhibitors and immune checkpoint inhibitors versus angiogenesis inhibitors alone","volume":"188","author":"Crocetto","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00395-024-01068-8","article-title":"Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors","volume":"120","author":"Gergely","year":"2025","journal-title":"Basic Res Cardiol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1550400","article-title":"Ici-induced cardiovascular toxicity: mechanisms and immune reprogramming therapeutic strategies","volume":"16","author":"Zheng","year":"2025","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025018001","article-title":"Cabozantinib and thromboembolism in patients with cancer: A systematic review, meta-analysis and retrospective study","volume":"10","author":"Eswaran","year":"2025","journal-title":"Blood Adv"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2023.12.010","article-title":"Cardiovascular Eligibility Criteria And adverse Event Reporting In combined Immune Checkpoint And vegf Inhibitor Trials","volume":"6","author":"Rankin","year":"2024","journal-title":"JACC CardioOncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21781","article-title":"Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: A multicentre study from the european academy of dermatology and venereology task force of dermatology for cancer patients","volume":"187","author":"Nikolaou","year":"2022","journal-title":"Br J Dermatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2016.12.001","article-title":"Cutaneous adverse effects of the immune checkpoint inhibitors","volume":"41","author":"Collins","year":"2017","journal-title":"Curr Probl Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102848","article-title":"Local administration of immunotherapy for patients with skin cancer: A systematic review","volume":"131","author":"Janssen","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab618","article-title":"Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: A safety meta-analysis","volume":"42","author":"Dolladille","year":"2021","journal-title":"Eur Heart J"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050532","article-title":"The evolving role of immune checkpoint inhibitors in hepatocellular carcinoma treatment","volume":"9","author":"Leone","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34004","article-title":"Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-ctla4 and anti-pd1 combination immunotherapy: incidence, management, and clinical benefit","volume":"128","author":"Patel","year":"2022","journal-title":"Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s12967-020-02612-5","article-title":"Revisiting the association between skin toxicity and better response in advanced cancer patients treated with immune checkpoint inhibitors","volume":"18","author":"Gulati","year":"2020","journal-title":"J Transl Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222186","article-title":"Risk of iraes in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage iii or iv melanoma: results from a matched case-control study","volume":"81","author":"Pla\u00e7ais","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009345","article-title":"Prophylactic il-23 blockade uncouples efficacy and toxicity in dual ctla-4 and pd-1 immunotherapy","volume":"12","author":"Ju","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.125788","article-title":"Vicious-cycle-breaking antiangiogenic nano-delivery systems potentiate and simplify the tumor vascular normalization strategy","volume":"681","author":"Qi","year":"2025","journal-title":"Int J Pharm"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008086","article-title":"Ich in primary or metastatic brain cancer patients with or without anticoagulant treatment: A systematic review and meta-analysis","volume":"6","author":"Giustozzi","year":"2022","journal-title":"Blood Adv"},{"key":"B62","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ccell.2025.01.008","article-title":"Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases","volume":"43","author":"Rodriguez-Baena","year":"2025","journal-title":"Cancer Cell"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab012","article-title":"Emerging principles of brain immunology and immune checkpoint blockade in brain metastases","volume":"144","author":"Fares","year":"2021","journal-title":"Brain"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.3461","article-title":"Immune-Related Adverse Events after Immune Checkpoint Inhibitors for Melanoma among Older Adults","volume":"5","author":"Schonfeld","year":"2022","journal-title":"JAMA Netw Open"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1760044\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T06:59:01Z","timestamp":1770879541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1760044\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":64,"alternative-id":["10.3389\/fimmu.2026.1760044"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1760044","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"article-number":"1760044"}}